Avadel Pharmaceuticals

AVDLNASDAQ
$14.57
$15.00
0.432.95%
Pre-Market: 6:59 PM EDT
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$29.00
Lowest Price Target1
$11.00
Consensus Price Target1
$21.00

Avadel Pharmaceuticals (NASDAQ:AVDL) Stock, Analyst Ratings, Price Targets, Predictions

Avadel Pharmaceuticals PLC has a consensus price target of $21, established from looking at the 48 latest analyst ratings. The last 3 analyst ratings were released from Needham, HC Wainwright & Co., and Craig-Hallum on May 9, 2024. With an average price target of $24 between Needham, HC Wainwright & Co., and Craig-Hallum, there's an implied 60.00% upside for Avadel Pharmaceuticals PLC from these 3 analyst ratings.

Analyst Trends and Forecast
0
0
0
0
Feb
2
Mar
0
0
0
0
Apr
0
0
0
0
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.3
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
HC Wainwright & Co.
Craig-Hallum
Piper Sandler
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Avadel Pharmaceuticals

Buy NowGet Alert
05/09/2024Buy Now46.67%Needham
Ami Fadia
→ $22ReiteratesBuy → BuyGet Alert
05/09/2024Buy Now80%HC Wainwright & Co.
Oren Livnat
$25 → $27MaintainsBuyGet Alert
05/09/2024Buy Now53.33%Craig-Hallum
Chase Knickerbocker
$22 → $23MaintainsBuyGet Alert
05/08/2024Buy Now46.67%Needham
Ami Fadia
→ $22ReiteratesBuy → BuyGet Alert
04/09/2024Buy Now46.67%Needham
Ami Fadia
→ $22ReiteratesBuy → BuyGet Alert
03/05/2024Buy Now46.67%Craig-Hallum
Chase Knickerbocker
$20 → $22MaintainsBuyGet Alert
03/05/2024Buy Now53.33%Piper Sandler
David Amsellem
$18 → $23MaintainsOverweightGet Alert
03/05/2024Buy Now93.33%Oppenheimer
Francois Brisebois
$27 → $29MaintainsOutperformGet Alert
03/05/2024Buy Now66.67%HC Wainwright & Co.
Oren Livnat
$21 → $25MaintainsBuyGet Alert
03/05/2024Buy Now46.67%Needham
Ami Fadia
$20 → $22MaintainsBuyGet Alert
02/06/2024Buy Now40%UBS
Ashwani Verma
→ $21Initiates → BuyGet Alert
12/20/2023Buy Now33.33%Needham
Ami Fadia
$19 → $20MaintainsBuyGet Alert
11/09/2023Buy Now26.67%Needham
Ami Fadia
$18 → $19MaintainsBuyGet Alert
10/04/2023Buy Now20%Needham
Ami Fadia
→ $18ReiteratesBuy → BuyGet Alert
09/25/2023Buy Now20%Needham
Ami Fadia
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now20%Piper Sandler
David Amsellem
$13 → $18MaintainsOverweightGet Alert
08/10/2023Buy Now20%Needham
Ami Fadia
→ $18ReiteratesBuy → BuyGet Alert
08/10/2023Buy Now40%HC Wainwright & Co.
Oren Livnat
→ $21ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now20%Needham
Ami Fadia
→ $18Reiterates → BuyGet Alert
07/05/2023Buy Now40%HC Wainwright & Co.
Oren Livnat
$17.5 → $21ReiteratesBuy → BuyGet Alert
06/30/2023Buy Now66.67%Oppenheimer
Francois Brisebois
$22 → $25MaintainsMarket OutperformGet Alert
06/30/2023Buy Now20%Needham
Ami Fadia
→ $18ReiteratesBuy → BuyGet Alert
06/12/2023Buy Now46.67%Oppenheimer
Francois Brisebois
→ $22ReiteratesOutperform → OutperformGet Alert
05/30/2023Buy Now20%Needham
Ami Fadia
$14 → $18Reiterates → BuyGet Alert
05/02/2023Buy Now73.33%LifeSci Capital
Patrick Dolezal
$17 → $26MaintainsOutperformGet Alert
05/02/2023Buy Now6.67%Ladenburg Thalmann
Matthew Kaplan
$14.5 → $16MaintainsBuyGet Alert
05/02/2023Buy Now46.67%Oppenheimer
Francois Brisebois
$20 → $22MaintainsOutperformGet Alert
05/02/2023Buy Now16.67%HC Wainwright & Co.
Oren Livnat
$14 → $17.5MaintainsBuyGet Alert
05/02/2023Buy Now-6.67%Needham
Ami Fadia
$12 → $14MaintainsBuyGet Alert
04/28/2023Buy Now-20%Needham
Ami Fadia
→ $12Reiterates → BuyGet Alert
04/17/2023Buy Now-26.67%Needham
Ami Fadia
→ $11MaintainsBuyGet Alert
04/03/2023Buy Now33.33%Oppenheimer
Francois Brisebois
→ $20Reiterates → OutperformGet Alert
04/03/2023Buy Now-26.67%Needham
Ami Fadia
→ $11Reiterates → BuyGet Alert
03/23/2023Buy Now-6.67%HC Wainwright & Co.
Oren Livnat
$13 → $14MaintainsBuyGet Alert
02/27/2023Buy Now33.33%Oppenheimer
Francois Brisebois
$19 → $20MaintainsOutperformGet Alert
02/24/2023Buy Now-26.67%Needham
Ami Fadia
→ $11MaintainsBuyGet Alert
02/07/2023Buy Now-13.33%HC Wainwright & Co.
Oren Livnat
→ $13Reiterates → BuyGet Alert
02/07/2023Buy Now-26.67%Needham
Ami Fadia
→ $11Reiterates → BuyGet Alert
11/30/2022Buy Now-26.67%Jefferies
Chris Howerton
$6.5 → $11UpgradeHold → BuyGet Alert
11/21/2022Buy Now-40%Needham
Ami Fadia
$8 → $9MaintainsBuyGet Alert
08/11/2022Buy Now-20%SVB Leerink
Marc Goodman
$6 → $12MaintainsOutperformGet Alert
08/10/2022Buy Now-40%Needham
Ami Fadia
$6 → $9MaintainsBuyGet Alert
08/10/2022Buy Now-46.67%Jefferies
Chris Howerton
$6 → $8DowngradeBuy → HoldGet Alert
05/31/2022Buy Now-60%Needham
Ami Fadia
$14 → $6MaintainsBuyGet Alert
05/27/2022Buy Now-13.33%HC Wainwright & Co.
Oren Livnat
$17 → $13MaintainsBuyGet Alert
05/27/2022Buy Now-60%SVB Leerink
Marc Goodman
$18 → $6MaintainsOutperformGet Alert
01/11/2022Buy NowNeedham
Ami Fadia
$16 → $15MaintainsBuyGet Alert
09/23/2021Buy Now13.33%Needham
Ami Fadia
Initiates → BuyGet Alert

FAQ

Q

What is the target price for Avadel Pharmaceuticals (AVDL) stock?

A

The latest price target for Avadel Pharmaceuticals (NASDAQ:AVDL) was reported by Needham on May 9, 2024. The analyst firm set a price target for $22.00 expecting AVDL to rise to within 12 months (a possible 46.67% upside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avadel Pharmaceuticals (AVDL)?

A

The latest analyst rating for Avadel Pharmaceuticals (NASDAQ:AVDL) was provided by Needham, and Avadel Pharmaceuticals reiterated their buy rating.

Q

When was the last upgrade for Avadel Pharmaceuticals (AVDL)?

A

The last upgrade for Avadel Pharmaceuticals PLC happened on November 30, 2022 when Jefferies raised their price target to $11. Jefferies previously had a hold for Avadel Pharmaceuticals PLC.

Q

When was the last downgrade for Avadel Pharmaceuticals (AVDL)?

A

The last downgrade for Avadel Pharmaceuticals PLC happened on August 10, 2022 when Jefferies changed their price target from $6 to $8 for Avadel Pharmaceuticals PLC.

Q

When is the next analyst rating going to be posted or updated for Avadel Pharmaceuticals (AVDL)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avadel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avadel Pharmaceuticals was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.

Q

Is the Analyst Rating Avadel Pharmaceuticals (AVDL) correct?

A

While ratings are subjective and will change, the latest Avadel Pharmaceuticals (AVDL) rating was a reiterated with a price target of $22.00 to $22.00. The current price Avadel Pharmaceuticals (AVDL) is trading at is $15.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.